PL1910839T3 - Gen TOM34 związany z nowotworem okrężnicy - Google Patents

Gen TOM34 związany z nowotworem okrężnicy

Info

Publication number
PL1910839T3
PL1910839T3 PL06781857.5T PL06781857T PL1910839T3 PL 1910839 T3 PL1910839 T3 PL 1910839T3 PL 06781857 T PL06781857 T PL 06781857T PL 1910839 T3 PL1910839 T3 PL 1910839T3
Authority
PL
Poland
Prior art keywords
tom34
colon cancer
related gene
cancer related
gene
Prior art date
Application number
PL06781857.5T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yoichi Furukawa
Hideaki Tahara
Takuya Tsunoda
Satoshi Matsushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1910839T3 publication Critical patent/PL1910839T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06781857.5T 2005-07-27 2006-07-21 Gen TOM34 związany z nowotworem okrężnicy PL1910839T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70326505P 2005-07-27 2005-07-27

Publications (1)

Publication Number Publication Date
PL1910839T3 true PL1910839T3 (pl) 2016-11-30

Family

ID=37499354

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06781857.5T PL1910839T3 (pl) 2005-07-27 2006-07-21 Gen TOM34 związany z nowotworem okrężnicy

Country Status (19)

Country Link
US (1) US8674059B2 (pl)
EP (1) EP1910839B1 (pl)
JP (2) JP5095603B2 (pl)
KR (2) KR101325194B1 (pl)
CN (1) CN101278196B (pl)
AU (1) AU2006273192B2 (pl)
BR (1) BRPI0613970B8 (pl)
CA (1) CA2616497C (pl)
CY (1) CY1117839T1 (pl)
DK (1) DK1910839T3 (pl)
ES (1) ES2584247T3 (pl)
HK (1) HK1115193A1 (pl)
HU (1) HUE027330T2 (pl)
PL (1) PL1910839T3 (pl)
PT (1) PT1910839T (pl)
RU (2) RU2526196C2 (pl)
SG (1) SG163614A1 (pl)
SI (1) SI1910839T1 (pl)
WO (1) WO2007013576A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008917A (es) * 2009-03-04 2011-09-09 Oncotherapy Science Inc Peptidos vangl1 y vacunas que incluyen los mismos.
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之melk胜肽及含此胜肽之疫苗
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
SG190407A1 (en) * 2010-12-02 2013-06-28 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
DK2771350T3 (en) * 2011-10-28 2018-04-30 Onco Therapy Science Inc TOP PEPTIDES AND VACCINES INCLUDING THESE
CN104168917A (zh) 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
US20170313771A1 (en) * 2014-08-26 2017-11-02 Atgen Co., Ltd. Antibody for Recognizing Specific Motif of WLS Protein, and Pharmaceutical Composition Comprising Same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0458841B1 (en) * 1989-02-17 1995-06-14 Chiron Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1250145A4 (en) 2000-01-03 2003-03-26 Argonex Pharmaceuticals Inc PEPTIDES DERIVED FROM ONCOGENE C-SKI FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) * 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP1581812B1 (en) * 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers

Also Published As

Publication number Publication date
JP2012125248A (ja) 2012-07-05
HK1115193A1 (zh) 2008-11-21
SI1910839T1 (sl) 2016-06-30
CN101278196A (zh) 2008-10-01
HUE027330T2 (en) 2016-09-28
SG163614A1 (en) 2010-08-30
KR101325194B1 (ko) 2013-11-06
EP1910839B1 (en) 2016-04-27
CA2616497A1 (en) 2007-02-01
JP2009502732A (ja) 2009-01-29
CN101278196B (zh) 2013-05-15
DK1910839T3 (en) 2016-07-04
CY1117839T1 (el) 2017-05-17
KR20130087639A (ko) 2013-08-06
BRPI0613970B1 (pt) 2019-10-29
AU2006273192B2 (en) 2011-09-01
BRPI0613970B8 (pt) 2021-05-25
JP5095603B2 (ja) 2012-12-12
US8674059B2 (en) 2014-03-18
AU2006273192A1 (en) 2007-02-01
RU2526196C2 (ru) 2014-08-20
RU2008107318A (ru) 2009-09-10
RU2449020C2 (ru) 2012-04-27
ES2584247T3 (es) 2016-09-26
BRPI0613970A2 (pt) 2011-02-22
EP1910839A1 (en) 2008-04-16
US20090214571A1 (en) 2009-08-27
CA2616497C (en) 2016-06-07
WO2007013576A1 (en) 2007-02-01
RU2011127868A (ru) 2013-01-20
PT1910839T (pt) 2016-07-14
KR20080040738A (ko) 2008-05-08

Similar Documents

Publication Publication Date Title
GB0719792D0 (en) Cancer biomarkers
IL187679A (en) Vector gardens
IL179812A0 (en) THE IMPORTANCE OF THE GENE HoxB13 FOR CANCER
GB0512707D0 (en) Gene expression technique
GB0517954D0 (en) Bayesian feature selection
HK1115193A1 (zh) 與結腸癌有關的 因子
EP1891047A4 (en) A 1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID SUITABLE FOR THE CHEMOTHERAPY OF CANCER
EP1937503A4 (en) DIFFERENTIAL
HK1108924A1 (en) Cancer prognostic methods
IL198354A0 (en) Genetic variations associated with tumors
GB0720953D0 (en) Slide
GB0525523D0 (en) Genetic process
GB0507685D0 (en) Cancer treatment
GB0504338D0 (en) Document wallet
EP1731160A4 (en) COMPOSITION FOR INHIBITING CANCER METASTAS
ZA200804281B (en) Electrionic vouchers
GB0417107D0 (en) Genes II
GB0508503D0 (en) Genes III
IL187241A0 (en) Gene-based algorithmic cancer prognosis
ZA200709735B (en) Gene-based algorithmic cancer prognosis
GB0426701D0 (en) Tumour suppressor genes
GB0408629D0 (en) Gene
GB0509340D0 (en) Gene over-expression
GB0409058D0 (en) Cancer axis
GB2441911B (en) Slide